How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

346 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Should Protease Inhibitors be Used for COVID-19?

, RCT ASC09 with ritonavir Lopinavir/ritonavir May 2020 NCT04315948 11 MC, OL, RCT ? Remdesivir ? lopinavir/ritonavir ? lopinavir/ritonavir with interferon ß-1a Standard of care March 2023 † The literature search covered antiretroviral HIV-1 protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir); and hepatitis C virus NS3/4A protease inhibitors (asunaprevir, boceprevir, grazoprevir, glecaprevir, paritaprevir

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

42. Should Protease Inhibitors be Used for COVID-19?

2020 NCT04315948 11 MC, OL, RCT ? Remdesivir ? Lopinavir/ritonavir ? Lopinavir/ritonavir with interferon ß-1a Standard of care March 2023 † The literature search covered antiretroviral HIV-1 protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir); and hepatitis C virus NS3/4A protease inhibitors (asunaprevir, boceprevir, grazoprevir, glecaprevir, paritaprevir, simeprevir, telaprevir and danoprevir). MOH-ACE COVID

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

43. COVID-19: Prophylactic Use of Hydroxychloroquine (HCQ)

There are currently no FDA approved medications for treatment of COVID-19; but several readily available oral medications have demonstrated possible activity against SARS CoV-2 including hydroxychloroquine, HIV-1 protease inhibitors (e.g., lopinavir-ritonavir, atazanavir, tipranavir), and azithromycin. None of these agents have been studied in large clinical trials (with or without placebo) to support their off label use in the ambulatory setting for the treatment/prevention of COVID 19 patients. The use

2020 Centre for Evidence-Based Practice, Penn Medicine

44. Kaiser Permanente National Cholesterol and Cardiovascular Risk Clinician Guide

or other protease inhibitors Use atorvastatin up to 20 mg, and 40 mg with caution Avoid max dose of any statin Avoid simvastatin and lovastatin Tipranavir Use rosuvastatin up to 20 mg Avoid atorvastatin, simvastatin, and lovastatin HEPATITIS C MEDICATIONS: Current therapy: Guidance: Avoid: Ledipasvir/sofosbuvir Use atorvastatin up to 40 mg Avoid rosuvastatin Simeprevir Use atorvastatin up to 40 mg or rosuvastatin up to 10 mg References: Statin package inserts. Lexicomp HIV medications: http

2018 Kaiser Permanente National Guideline Program

46. Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic hepatitis C genotypes 1 and 4

: efavirenz atazanavir darunavir lopinavir saquinavir tipranavir. Other HIV medicines not recommended for co-administration with GRZ/EBR because they may reduce the therapeutic effect of GRZ/EBR are: etravirine elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or alagenamide (fixed-dose combination). Patients receiving opioid-agonist therapy People who inject drugs comprise a major population of patients affected by hepatitis C infection that is rarely included in studies of DAAs. The C (...) concentration. This can increase the risk of ALT elevations. GRZ/EBR is contraindicated with OATP1B1/3 inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations, including: rifampicin atazanavir, darunavir, lopinavir, saquinavir and tipranavir ciclosporin. Precautions Caution should be used when co-administering GRZ/EBR with: strong cytochrome P450 3A4 inhibitors (eg, ketoconazole and ritonavir), which may lead to increased concentrations of elbasvir and grazoprevir

2018 National Prescribing Service Limited (Australia)

47. Darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza) - HIV Infections

standard deviation SmPC Summary of Product Characteristics SOC system organ class SQV saquinavir TAF tenofovir alafenamide TDF tenofovir disoproxil fumarate TFV tenofovir TFV-DP tenofovir-diphosphate TLOVR time to loss of virologic response tmax actual sampling time to reach the maximum observed analyte concentration TPV tipranavir UGT uridine diphosphate glucuronosyltransferase ULN upper limit of normal UPCR urine protein to creatinine ratio U(H)PLC ultra-high performance liquid chromatography UV

2017 European Medicines Agency - EPARs

48. Kaiser Permanente National Dyslipidemia Clinician Guide

, or saquinavir (ritonavir boosted) Use atorvastatin up to 20 mg, or rosuvastatin up to 20 mg Avoid simvastatin and lovastatin Nonritonavir boosted or other protease inhibitors Use atorvastatin up to 20 mg, and 40 mg with caution Avoid max dose of any statin Avoid simvastatin and lovastatin Tipranavir Use rosuvastatin up to 20 mg Avoid atorvastatin, simvastatin, and lovastatin HEPATITIS C MEDICATIONS: Current therapy: Guidance: Avoid: Boceprevir Use atorvastatin up to 40 mg or rosuvastatin up to 20 mg Avoid

2017 Kaiser Permanente National Guideline Program

49. BHIVA guidelines on the management of HIV in pregnancy and postpartum

population has been excluded [24]. • Darunavir, efavirenz, indinavir, raltegravir and rilpivirine have been shown to have congenital malformation rates within the expected range, and a congenital malformation rate greater than 1.5-fold higher than in the general population has been excluded. • For newer agents (cobicistat, dolutegravir, elvitegravir and tenofovir alafenamide) and a number of less commonly prescribed older compounds (saquinavir, fosamprenavir, enfuvirtide, tipranavir, maraviroc

2019 British HIV Association

50. Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01068925 Recruitment Status : Completed First Posted : February 15, 2010 Last Update Posted : January 25, 2011 Sponsor: GlaxoSmithKline

2010 Clinical Trials

51. Metabolism-Mediated Drug Interactions Associated with Ritonavir-Boosted Tipranavir in Mice Full Text available with Trip Pro

Metabolism-Mediated Drug Interactions Associated with Ritonavir-Boosted Tipranavir in Mice Tipranavir (TPV) is the first nonpeptidic protease inhibitor used for the treatment of drug-resistant HIV infection. Clinically, TPV is coadministered with ritonavir (RTV) to boost blood concentrations and increase therapeutic efficacy. The mechanism of metabolism-mediated drug interactions associated with RTV-boosted TPV is not fully understood. In the current study, TPV metabolism was investigated

2010 Drug Metabolism and Disposition

52. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Full Text available with Trip Pro

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. The effects of tipranavir/ritonavir (TPV/r) on hepatic and intestinal P-glycoprotein (P-gp) and cytochrome P450 (CYP) enzyme activity were evaluated in 23 volunteers. The subjects received oral (p.o.) caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, and midazolam and digoxin (p.o. and intravenous (i.v.)) at baseline, during the first three

2010 Clinical pharmacology and therapeutics Controlled trial quality: uncertain

53. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. (Abstract)

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. Despite being among the most potent protease inhibitors, the use of tipranavir (TPV) is hampered by a high pill burden and frequent side effects compared with other boosted protease inhibitors. A total of 10 patients receiving TPV/ritonavir (TPV/RTV) 500/200 for longer than 6 months were randomized to stay on the same dosing schedule or switch to TPV/RTV 500/100. Although

2010 Therapeutic drug monitoring Controlled trial quality: uncertain

54. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients. (Abstract)

Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients. This study characterized the pharmacokinetic effects, safety, and antiretroviral activity of three different doses of the nonpeptidic protease inhibitor tipranavir, in combination with ritonavir administered twice daily for 28 days, on a number of triple-combination regimens containing a nonnucleoside reverse transcriptase (...) combinations of tipranavir and ritonavir (1250/100 mg, 750/100 mg, and 250/200 mg) in addition to their antiretroviral (ARV) regimen for the next 22 days. The effects of twice-daily tipranavir and ritonavir combinations on the steady-state pharmacokinetics of the antiretrovirals were assessed by comparing pharmacokinetic parameters at baseline and after 3 weeks of coadministration.No clinically relevant changes were observed in the Cmin, Cmax, or AUC parameters for nevirapine, efavirenz, lamivudine

2010 HIV clinical trials Controlled trial quality: uncertain

57. Contraception - emergency

, fosamprenavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Non-nucleoside reverse transcriptase inhibitors: efavirenz, nevirapine Respiratory drugs Bosentan Central nervous system drugs Modafinil, aprepitant Herbal preparations St John's wort Data from: [ ] Basis for recommendation Basis for recommendation These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines Emergency contraception [ ], and Drug Interactions with hormonal contraception

2019 NICE Clinical Knowledge Summaries

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>